Další formáty:
BibTeX
LaTeX
RIS
@article{2268564,
author = {Pandey, Shashank and Jirásko, Michal and Lochman, Jan and Chvátal, Alexandr and Dvorakova, Magdalena Chottova and Kučera, Radek},
article_number = {9},
doi = {http://dx.doi.org/10.3390/jpm12091485},
keywords = {induced pluripotent stem cells (iPSCs); Alzheimer's disease; Parkinson's disease; diabetic neuropathy; spinal cord injury; personalized medicine},
language = {eng},
issn = {2075-4426},
journal = {Journal of Personalized Medicine},
title = {iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine},
url = {https://www.mdpi.com/2075-4426/12/9/1485},
volume = {12},
year = {2022}
}
TY - JOUR
ID - 2268564
AU - Pandey, Shashank - Jirásko, Michal - Lochman, Jan - Chvátal, Alexandr - Dvorakova, Magdalena Chottova - Kučera, Radek
PY - 2022
TI - iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine
JF - Journal of Personalized Medicine
VL - 12
IS - 9
SP - 1-18
EP - 1-18
PB - MDPI
SN - 20754426
KW - induced pluripotent stem cells (iPSCs)
KW - Alzheimer's disease
KW - Parkinson's disease
KW - diabetic neuropathy
KW - spinal cord injury
KW - personalized medicine
UR - https://www.mdpi.com/2075-4426/12/9/1485
N2 - In the past, several animal disease models were developed to study the molecular mechanism of neurological diseases and discover new therapies, but the lack of equivalent animal models has minimized the success rate. A number of critical issues remain unresolved, such as high costs for developing animal models, ethical issues, and lack of resemblance with human disease. Due to poor initial screening and assessment of the molecules, more than 90% of drugs fail during the final step of the human clinical trial. To overcome these limitations, a new approach has been developed based on induced pluripotent stem cells (iPSCs). The discovery of iPSCs has provided a new roadmap for clinical translation research and regeneration therapy. In this article, we discuss the potential role of patient-derived iPSCs in neurological diseases and their contribution to scientific and clinical research for developing disease models and for developing a roadmap for future medicine. The contribution of humaniPSCs in the most common neurodegenerative diseases (e.g., Parkinson’s disease and Alzheimer’s disease, diabetic neuropathy, stroke, and spinal cord injury) were examined and ranked as per their published literature on PUBMED. We have observed that Parkinson’s disease scored highest, followed by Alzheimer’s disease. Furthermore, we also explored recent advancements in the field of personalized medicine, such as the patient-on-a-chip concept, where iPSCs can be grown on 3D matrices inside microfluidic devices to create an in vitro disease model for personalized medicine.
ER -
PANDEY, Shashank, Michal JIRÁSKO, Jan LOCHMAN, Alexandr CHVÁTAL, Magdalena Chottova DVORAKOVA a Radek KUČERA. iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine. \textit{Journal of Personalized Medicine}. MDPI, 2022, roč.~12, č.~9, s.~1-18. ISSN~2075-4426. Dostupné z: https://dx.doi.org/10.3390/jpm12091485.
|
